Seeking Alpha
We cover over 5K calls/quarter
Profile| Send Message|
( followers)

WebMD Health Corp (NASDAQ:WBMD)

March 06, 2013 4:00 pm ET

Executives

Cavan M. Redmond - Chief Executive Officer, Director and Member of Executive Committee

Analysts

Mark May - Barclays Capital, Research Division

Mark May - Barclays Capital, Research Division

I think maybe for the first time today. I'm Mark May, I'm one of the Internet analysts here at Barclays. And it's my pleasure to have Cavan Redmond, Chief Executive Officer of WebMD Health, with us. I appreciate it, thanks.

Cavan M. Redmond

Thanks, me too.

Mark May - Barclays Capital, Research Division

He wanted me to read something for you. So the explanatory paragraphs at the beginning of WebMD's most recent annual report concerning forward-looking disclosures and related risks and uncertainties also apply to any forward-looking disclosures made during this presentation. Additional information concerning the risks and uncertainties can be found in that annual report and in WebMD's other SEC filings.

Question-and-Answer Session

Mark May - Barclays Capital, Research Division

So maybe if you could just get us a started, if you wouldn't mind, giving us a brief introduction to WebMD for the folks in the audience that aren't aware, probably not many, and maybe also appropriate to give us a little background about yourself and why you decided to join WebMD?

Cavan M. Redmond

Sure. Thanks for the opportunity. Let me start with WebMD. So WebMD is the go-to place on the Internet for really understanding both healthy living and for disease-specific information. And when I think of WebMD, it has really 3 key brands under it: WebMD, which is where consumers go, patients go and caregivers go to really get a deep understanding of what's happening in either a disease area they're interested in, or if they've got questions about information they've received from health care providers, or when they're looking for essentially healthy living information in order to do -- to live a better life. And then we have Medscape, which is the leading physician and health care portal for providing a deep understanding and relationship to the medical information that's out there and to supplement what they're doing every day at point of care all the way through to other information that a physician or other health care provider. And then of course we have the WebMD Health Services, which has a service to businesses and others through the HR function. So when you look at the company, we have an incredible breadth in health care. And are really at the intersection of where health care is changing and the consumerism that's occurring in health care and at the same time, have the benefit of being a tech company because, obviously, we serve that information through some of the most interesting ways to deliver it in a multiscreen platform.

Mark May - Barclays Capital, Research Division

Yes. What about a little background on your decision to join WebMD and what attracted you to the challenge?

Cavan M. Redmond

Sure. I've been fortunate in my career to be able to work in the R&D organization, a commercial organization, on the pharmaceutical and the biotech side, but also in the consumer and the nutritional side. So I've seen a variety of impact that health care can have on people throughout the world. One of the things that attracted me most to WebMD was that I believe that there's a major change occurring in the United States over the next several years in health care. I think it's been much more of a consumer experience than it has ever been before. And when I looked at the strengths of WebMD and what -- the places that it had the potential to go, I thought there was a great opportunity there, especially with my background. And I believe that as a company, it can play a significant role in the changing health care environment as we go through the next, really, 2 or 3 years of major changes in the U.S. health care system.

Mark May - Barclays Capital, Research Division

So one of the many initiatives that you've taken on since joining is -- seems to have been around kind of the rightsizing of the organization. So maybe if you could just talk to us a little bit about why that was necessary, maybe some -- give us some specifics about what you actually have done? And -- yes.

Cavan M. Redmond

Yes. So in December, we announced that as part of taking a look at the overall company, that we had to unfortunately eliminate about 250 positions, which is always difficult. But we did it with an eye towards where do we want to start positioning ourselves in 2013 and beyond, and really, under a couple of key principles. One is focusing on becoming more nimble, taking a look at where the marketplace was going and where we need to put the resources. The other is taking a look at what opportunities we believe that we could create in the marketplace. So looking at a couple of imperatives that we're going to focus on that include things like more meaningful connectivity between patients and physicians, taking a look at the way the Affordable Care Act is going to roll out in the United States and the changes that it's going to make. And also making sure that we have, under everything we do, an approach of operational excellence. We're focusing on improving our capabilities through processes and procedures that benefit our clients, our users and of course, our employees. So we made those cuts. We think it put us in good shape for looking at 2013 and beyond and beginning to essentially look at opportunities going forward.

Mark May - Barclays Capital, Research Division

Maybe if we could talk a little bit about kind of how you consider the competitive landscapes out there in terms of the alternatives that your customers have, talk -- maybe some of us are more familiar on the consumer side, but talk a little bit about where you see the competitive landscape on the consumer side. How you're trying to differentiate the webmd.com experience versus the other alternatives that are out there. And then on the Medscape side, which maybe we're, those of us in the audience, certainly not myself, are as familiar with the other alternatives that are out there for physicians and other health care professionals.

Cavan M. Redmond

I'd love to. So when I think about health care and what's happening right now, if you think about what really happens to individuals, it's a very personal journey. So a simple example is this. If you happen to have a child in college and they call you up on a Saturday morning complaining about a headache and a stomachache, they're talking about the hangover they're dealing with. But then, they're talking more and more about the pain they have in their lower abdomen. As parents, you might be thinking appendicitis, they're thinking aspirin and water. And if you think about what your next reaction is, it's actually to go and seek information, right? So if you're the college kid, you're looking for the next remedy. If you happen to be the parent, you're looking to make sure there's not something more serious. And that's really how health care works, which is, is it's a dialogue and it's a constant looking at what are the possibilities and how do I educate myself. And I think that's where health care is going to go. So part of what we've been positioning in the past, and we'll continue to in the future, WebMD, is tools and capabilities that make it easy for people to have that health care journey. So for example, we have something called Symptom Checker, which allows you to essentially click on an anatomy and be able to go deeper and deeper into potential signs and symptoms and answer questions for you, all the way through to our WebMD answers, which is allowing you to go into a community experience and ask questions that can be answered by a variety of people, peers, professionals and others. So when we take a look at it from a WebMD standpoint, we believe that on the consumer side, it has to be personal, it has to be something that allows you to not just come back multiple times, but allow you to get the information you need at the time that you need it. The other change that has been made over the period of time is we have what we call a multiscreen experience. So going back to the parent and the college student, the college kid is probably on his iPhone, taking a look at what his solutions are, the parent may be at their desktop and our belief is that your multiscreen experience has to be seamless so that you're able to find the right information, have that right contextual information with the device that you choose at the time that you choose it. So when I look at where we're positioning ourselves is as more and more information needs to be gathered by the individual, we want to make sure that, essentially, we are where they are with the devices that they need. On the Medscape side, we have a world-class team on the Medscape side who understand the editorial content that a publisher can produce that makes a difference to health care professionals. So we have a very strong news desk, where we're able to provide information in pretty much real-time. We cover almost all of the major medical conferences and are able to update. And then we have deeper programs like our Medical Education group, which does approximately 60% of the online medical education in the United States. So we have a very strong relationship with the health care professionals. And when we look at the strength of the company, having a Medscape and a WebMD under one umbrella is a unique position in the industry.

Mark May - Barclays Capital, Research Division

And on the Medscape side, who are some of the -- who are you competing with for lion's share there? And how would you describe your differences?

Cavan M. Redmond

When I take a look at -- on the competitive landscape there, you're really looking at a number of smaller companies and being somebody who focuses on competition a lot, I take all competition seriously. So too many to name. But I'd answer it the other way, which is, the other thing you're really addressing is the changing marketplace. So if it was just competition, you'd gear yourself, taking a look at competition and adjust. But what's really happening out there with the health care professionals is, as the pharmaceutical industry changes, as hospitals are changing and private practices are, their needs are changing. So it's really, if you will, a race to be able to meet where the physicians and other health care providers are going. And we think we're extremely well-positioned, especially in areas of being able to provide information at point of care, so that you're able to actually get certain information you need, either on formulary or disease information, all the way through to the newest information for a particular therapeutic area. So our concentration also is on where we think health care is going to go over the next year or 2 and making sure that Medscape is continuing to be the place that those physicians and health care providers go.

Mark May - Barclays Capital, Research Division

Right. My sense is -- has been that, maybe especially on the consumer side of the business, that pharmaceutical advertisers a couple of years ago were maybe reluctant to go into some of the newer, seedier parts of the Internet for advertising. Maybe because of regulatory or regulatory uncertainty reasons, or a variety of reasons that maybe that's changed over time. So maybe can you help us think through the mind of a pharmaceutical advertiser, and maybe -- we clearly have seen how budgets have moved from TV and other offering channels to online. But maybe help us think about how the online piece of that budget has maybe changed over the last couple of years and where you see that going in terms of the channels and where they're spending their marketing dollars?

Cavan M. Redmond

Yes, and as a former marketer head, some of those concerns -- I can give you the kind of the personal view of that, too, which is, though the Internet and digital media is ubiquitous right now, if you think about it, it's a still relatively young industry, especially when you think about health care, which is a very highly regulated industry. These are new tools and techniques that are coming to bear. And in fact, when you look at the FDA and other regulatory bodies, they're still formulating a lot of the rules that are still yet to come that will help to shape this whole field. But historically, health endemic sites were not just the safest place to advertise, it was the most comfortable. It was very similar to what we were used to in other forms. So it essentially made it easy to port that kind of concept over. In more recent years, what you find is that in the same way that the Internet allows you to do more things, that the consumers you are trying to reach are also trying to do different things. So you have to relook at that. And what's happened is that both on the pharmaceutical advertising side and other health care advertising, the identifying other sites to go to has become essentially a part of the decision-making process. So when you look at the world that we compete in, we compete in, obviously, in endemic health care, but also in lifestyle and others. So one of the adjustments that we have made is taking a look at where the pharmaceutical industry is now and what are the opportunities there and for other health care advertisers. And we've upgraded things like our healthy living site, which is essentially allowing individuals who are leaning forward on the health care side to also get recipes and just general, healthy living and vaccination and other information and blending it in with our endemic health care site. And we think that that's going to be a much more robust opportunity for people to understand the unique position we hold in health care and allow us to compete extremely well in the future.

Mark May - Barclays Capital, Research Division

How do you see your, particularly on the consumer side, how do you see your mix of revenue, your ad revenue, changing over time from kind of Rx to lifestyle, non-Rx?

Cavan M. Redmond

I think both will continue to be important in the future. I believe that -- I have a fundamental belief that I believe research space companies like pharmaceutical industry, even though they go through ups and downs, are an important part of the health care system. And like any industry, they have the potential to continue to grow in the future. But when I think about our offerings, I'm really trying to focus on making sure that we have the opportunity to both the CPG and the Pharma side, where I think the opportunity is going to lay, as we take a look at both of those, is making sure that we match their reality to our programs, if you will. We're looking at programs that match kind of their review cycles, taking a look at things that are more within the execution within a shorter period of time. And while we have an incredible opportunity for services and products, we usually bundle them, taking and unbundling them and providing those individual offerings as opposed to more complex ones, were all steps that we're taking that I think begin to meet a different need to the consumers, or the advertisers are going to have. The one caution I have, though, is we still see, when we talk to our end clients, and some of the research that we ran last year is, the visibility for where they're going to make purchasing decisions is still about 7 months out. So if you think about strategic plans that used to be 5 years, budgets that used to be 12 and 18 months and rolling, I'm seeing clients that are looking at 6 and 7 months as kind of the visibility that they have into what they're spending or what their needs are going to be. So we're adjusting.

Mark May - Barclays Capital, Research Division

Okay. I'll have to ask the patent cliff issue question. What sort of inning are we in? Some investors are asking me, it feels like 2013 is kind of the trough and it's a base and you grow from here. What sort of headwind does that particular issue represent for WebMD this year? And maybe if it's possible for you to -- if you were to strip out the impact of revenue that's lost or goes away as a result of that, what does revenue look like, the revenue trend look like, excluding the impact of that?

Cavan M. Redmond

So looking at the pharmaceutical industry and patents in general, I'm not a good sports numbers guy, so I'll stay away from the inning part. But I'll give you kind of where I think the industry is. The last several years have seen some of the largest products go generic, and we've all watched that. But it's also had a rapid succession of a large number of those products going generic in a very short period of time. And when I look at it, a number of things happen in the industry, which are very important in terms of understanding what the dynamics are. One is, it requires them to essentially resize and restructure. So even if you had a successful launch, the impact of generic would still require you to relook at the totality of your infrastructure and reduce. In addition to that, regulatory filings, even though the number of approvals have gone up in the last year, the time it takes to get those approvals, the robustness of those packages and when they're expected to be approved, are all still subject to essentially the changes in the regulatory environment. So when I take a look at it from what's happened in the last few years is, I think the pharmaceutical industry has gone through an enormous amount of change, understanding how to work in essentially a continually changing environment. I used to work with a CEO who said, that it was -- in Pharma, it was going to be continuous whitewater for a number of years. And I think that's true. But if you get used to how to paddle in that and understand kind of what that trend looks like, you can manage through that. And I think that's what a lot of pharmaceutical executives and their teams have been doing. For those of us who are supplying them with capabilities, what it's meant is an adjustment, also, right? Because you have to take a look at, so what are their needs, what's the timeframe they have and make those adjustments. So though each and every year will have different patents going off at different periods of time, I think that there's becoming more and more institutional knowledge in the pharmaceutical industry about how to handle these drops and how to blend them with new product launches. But I would caution that there's still a lot of uncertainty out there, including this year, because it is a time of great change in the industry.

Mark May - Barclays Capital, Research Division

And if you look at the charts, it's not just -- it doesn't end this year. I mean, it doesn't...

Cavan M. Redmond

No, it doesn't. You hit the key point, Mark, is if you look at the numbers of products that are going off patent, it goes forever. I mean, it's going to be a continuous cycle. So some large products go in 1 year and -- but some smaller ones go the following year. Each have the same impact on an organization, so that's why, I think, the concept of that constant change and churn is important. And being able to navigate that in the long term is going to be key in order to be long-term successful.

Mark May - Barclays Capital, Research Division

A question around kind of, if you think about old WebMD and new WebMD, any meaningful changes in like the philosophy of the business? One of the hard philosophies of the company historically was 100% owned and operated. Except for there was the drugs.com thing, but 100% owned and operated, 100% direct sold. There were -- there were sort of these philosophies that were stuck to. Are there -- and maybe I'm not thinking of all of them off the top of my head, but are there -- any of those that you're sort of breaking down, that you're thinking differently these days about? And maybe not choosing the 2 I brought up, but anything to help us think about how probably the business is being run and the way you're tackling the opportunities?

Cavan M. Redmond

Yes. So let me give you a couple of thoughts and then give you some real examples that might be useful. So it's hard to comment on the past because it was a successful company and did some tremendous things. But as the market changed and continues to change, I look at where we can make changes to either get ahead of the challenges and be able to incorporate them in or essentially understand the changes and the potential impact. And part of that is taking a look at where we have opportunities to work differently. And I'll give you 2 examples. Simple example is the recent announcement we made on Monday with QUALCOMM, which is essentially taking 2 industry leaders, QUALCOMM on the communication and the technology side, and of course, ourselves on the health care side, and taking a look at how to address the incredibly interesting area of essentially personalization of devices and measurement tools that are becoming a new industry. In and of ourselves, neither of us could have done that by ourselves. But long term, we believe working together will be beneficial to consumers. So that's one way of looking at external collaborations. The other is also taking a look at what our customers need and ways that we can use our capabilities in unique ways. So one example is in the cough, cold, flu season this year, we partnered with Reckitt Benckiser to take a look at a different way to look at cough, cold and flu. Using our Symptom Checker and other proprietary methodologies, we essentially were able to track the cough, cold and flu system -- season this year in a different way, that allowed us to see where it was developing on a local zip code level all the way through to on a national level, providing essentially a different way of looking at our capabilities. Still protecting the privacy of our consumers, which is extremely important, but providing a cutting-edge way to look at information that's highly accurate. And we believe provided and will provide essentially insights that would never have been gained another way. That required a totally different capability from a team that was put together. It's very much a matrix cross-functional team that looked at what is the issue trying to be solved and brought new solutions to it. So I think we have a highly, highly talented team that's capable of essentially looking through the business issues that companies are facing now and being able to apply it in real-time.

Mark May - Barclays Capital, Research Division

Can you talk a little bit about that? Because early on, you brought in some really high-caliber new members to the team. Can you talk about a few of those? Organizational changes, if possible?

Cavan M. Redmond

Yes. Easily, the way I think about it is there's incredible talent within the company and of course, in an environment like we are, talent outside the company. And what I strive to do is get a good balance of internal talent with some new skill sets and new talent from the outside. And I think what that does is allows you to balance the best of both worlds, which is to take an incredibly complicated market and constantly taking a look at applying those capabilities. The other thing we've done internally, too, is taking a look at a number of the individuals we had and asked them to step into new roles in order to essentially apply new thinking to some of the new challenges. We'll continue to do that, because I think that by being able to take talent and use it in a unique way, will give us, in the long term, a competitive advantage, because I strongly believe that the strength of the company, besides the brands that we have, is the ability of individuals to step forward and make an enormous difference in what is a very complicated market.

Mark May - Barclays Capital, Research Division

Great. Maybe we can see if there's some questions out in the audience.

Unknown Analyst

You made some pricing changes to how you charge your customers. Could you talk about -- there have been comments about increased flexibility and such. Could you just talk about what the changes were and when they were implemented?

Cavan M. Redmond

Yes, as -- when we were -- in the end of 2012, we took a look at essentially what the value proposition for each of our products were and what the -- how we configured them. So we spent a lot of time essentially reconfiguring our products and unbundling from, if you will, packages to individual products and taking a look, especially at products and services that had essentially met the medical regulatory review cycle that companies were facing, so that it could go through with the timing that was needed. In the areas that we needed to, we did adjust pricing. But a lot of what we did was essentially simplify the product line, so that the customers could understand it, trained up our sales force and our marketing teams so that we could essentially explain the differences in those programs and we'll see, throughout this year, what the effect of that would be.

Mark May - Barclays Capital, Research Division

So just to, I don't know if simplify, but just try to explain what you're referring to differently. Are you talking about going from kind of sponsorship-related programs where someone is taking over the diabetes site -- section of the site for a 6- or 12-month period, to being more -- allowing them to be more nimble around their own product cycle, and can you just...

Cavan M. Redmond

Yes, maybe -- I think I've got an easy way to look at it. Historically, what marketers want to be and what WebMD did a great job of supplying was essentially complicated marketing and selling programs that were multidimensional. And it was at a time when, of course, that was what the pharmaceutical industry wanted and obviously, the consumers wanted, because you need both to be satisfied. But as times change, those programs are actually very difficult to get through your medical reviews, because they require multiple reviews and because each part of it has to be looked at. So we essentially break them into smaller pieces, and that way, companies can look at it and match their essentially cycle with...

Mark May - Barclays Capital, Research Division

So you might have been bundling CME-related sponsorships with WebMD sponsorships, with banner, front-page takeovers to a variety of different elements within a package?

Cavan M. Redmond

Little different. CME we never bundle, CME is completely independent, just for clarification, given its nature, because it's accredited and separate. But in terms of a consumer program, you may have banner ads, you may have destinations and other information and complete or created as a complete program and then run all of the pieces once they're all approved. Now you may just run your banner ads or you may run your sponsorship sites at different times or at different parts of your program life cycle. And that's true, quite frankly, for a lot of the programs that pharmaceutical companies run now, which is, we used to think about being able to market programs that essentially had all the elements, and you roll them out simultaneously. It's harder and harder to do in today's environment, given the changes that have occurred.

Mark May - Barclays Capital, Research Division

Any other questions?

Unknown Analyst

Just looking back at this past quarter, there's a pretty big difference between what you -- you talked the sequential stepdown, you talked about on the last quarter's call versus what we saw. And I think that -- we look at that and think, the guidance you gave for the year, for the back half, looks quite conservative. Can you reconcile what -- was it this change in sort of pricing and flexibility that really brought in higher volume? Or what was the big change that occurred in the way you guided for Q4 versus what we saw?

Cavan M. Redmond

When I think about what we focused on as a company and especially throughout Q4 and we'll continue to focus on in 2013, I've used the umbrella name of operational excellence, which is just focusing on organizationally how we work and where we can get improvements in our processes or procedures. And if you will, a lot of the basics, and that's a multifactorial program. I wouldn't say there's one thing or another that has an impact, it involves some, increasing our ability to train, increasing our focus on customer feedback, understanding how flexible we need to be in the marketplace and understanding where the market is going to go, both short term and long term. So we'll continue to take a look at how we operate and where the opportunities are to become more efficient in the marketplace. And then, of course, that has to be balanced with trying to understand that our customers have a shorter timeframe in terms of what they can see, the 7 months I mentioned. So we're also very cautious about trying to get too far ahead of where the customers are and really help them to meet their needs. And creating our internal processes to match that.

Unknown Analyst

Just to go back to that pricing plan, what was the reaction to all those changes? Did everybody -- I mean, was -- did most companies take advantage of the broken up pieces and do it -- buy it that way? Or did they stick with the original combined plans?

Cavan M. Redmond

Different companies, because they have different needs, have done different things. So if I were to characterize it, I'd say, as a company, we're trying to be much more flexible and much more customer-centric in what we do. So each company, of course, is looking for different things out of their programs. But the ability to be more customer-centric and to be more flexible is the beginning of essentially a different dialogue with many of those customers.

Mark May - Barclays Capital, Research Division

Can you -- maybe you won't be able to provide specific numbers, but maybe just magnitude in terms of CPM differences between kind of the endemic Rx advertiser and more the lifestyle advertiser?

Cavan M. Redmond

We really don't provide those numbers for various reasons, so, but...

Mark May - Barclays Capital, Research Division

Is it fair to say that the Rx advertiser is at a premium to the lifestyle?

Cavan M. Redmond

Yes, actually, if you would, I'd say it's slightly different. What I'd say is, in the world of CPG, where it's a totally different needs state from an advertising standpoint, those are -- it's a different competitive set, right, because when you're looking at consumer packaged goods products, and the way you can flight those types of programs because they don't have the regulatory burden that a pharmaceutical will, you have different opportunities there. The pharmaceutical, I don't think of as premium price, what I think of it as is it matches the value you have to provide, because the regulatory hurdles are greater. Also, the ability to meet those needs require a different skill set. So it's more managing, if you will, the differences in those types of markets.

Mark May - Barclays Capital, Research Division

As you branch more and more into the lifestyle area, does that require a different talent base? I mean, it feels like it's more push based versus pull in terms of how you interact with users. It feels like there's a different mindset in terms of the content and maybe even the way that you market and drive customers in and keep them engaged. How are you thinking about -- are you having to build kind of a separate organization to manage that?

Cavan M. Redmond

Yes. So we bundle that under healthy living. And again, if you go onto our site and go into the healthy living area, it does have a different look and a different feel than an endemic therapeutic area. So a great way to contrast it is, if you're going in and looking for information on renal cell carcinoma, you're looking for -- you're very specific. And the look and the feel for that is significantly different than those who are trying to look for, essentially, food and fitness or for vaccinations. So what we try to do is make sure that the experience matches what the consumer's mindset would be or in the other case, the patient's mindset would be and make sure that, that experience matches. And it does require different skill sets, it requires, if you will, different ways of thinking. And I think that's one of the unique capabilities that we have is that we can hit an understanding of what it takes to understand health care from a lifestyle standpoint and then for some of the most challenging diseases that we can imagine. But it's different ways of looking at it, different capabilities and also making sure that you match the user experience to both.

Mark May - Barclays Capital, Research Division

And on the healthy living side, are you doing marketing to drive customer acquisition? Or would you look to -- it would seem like it might work, it might be more relevant.

Cavan M. Redmond

Yes. What's interesting for WebMD is we're still driven by endemic traffic. So from just the search results, be it Google or the other engines. So we're not -- we don't acquire our traffic. It's still pretty much the organic traffic that has historically grown the company, and that's still the basis of the traffic that we receive. So that's been an incredible strength that continues today.

Unknown Analyst

[indiscernible] presented this morning. I guess they have a competing site or maybe it's a complementary site. It sounds like it's similar to this healthy living site. How does that enter into the market? Is the market just growing so much, there's room for both of you? Have they taken some of the share away from you? How do you sort of view the marketplace as a whole?

Cavan M. Redmond

Yes, I wasn't at their presentation, so I kind of don't know -- yes, I would hope so. I think that when you take a look at the health care field, especially in the digital area, there's different value propositions that different companies provide. I think our uniqueness in the marketplace and our value proposition allows us to take a look at what a variety of customers need and essentially be the go-to site for that. So like any competitive industry, you look at everything that's going on there. I think our unique selling point and certainly our consumers bear it out is, where's the traffic going and how are people using the site? So we've been very pleased with how we've developed and how we compete.

Mark May - Barclays Capital, Research Division

All right. I think that we're out of time. I appreciate you being here. Thanks, Cavan.

Cavan M. Redmond

Mark, thank you very much. I appreciate it.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!

Source: WebMD Health's CEO Presents at Barclays Internet Connect Conference (Transcript)

Check out Seeking Alpha’s new Earnings Center »

This Transcript
All Transcripts